Crohn's Disease Activity Index (CDAI)
Measures Crohn's disease activity over one week. The standard index for clinical trials. Remission: <150. Moderate-severe disease: 220–450. Severe: >450.
Score interpretation
CDAI <150 — clinical remission
→ Maintain current therapy; routine monitoring
CDAI 150–219 — mild active disease
→ Optimise current therapy; consider step-up; monitor closely
CDAI 220–450 — moderate to severe disease
→ Intensify therapy (biologics, steroids); gastroenterology review; consider hospital admission
CDAI >450 — severe disease
→ Urgent hospitalisation; IV steroids or biologic induction; surgical consultation
Interpretation bands for the CDAI. Apply clinical judgement and local guidance.
References
- Best WR et al. Development of a Crohn's disease activity index. Gastroenterology. 1976;70(3):439–444.
Related
Curated clinical cross-links plus same-class fallbacks.
- Harvey-Bradshaw Index for Crohn's Disease · Inflammatory Bowel Disease
- Mayo Score for Ulcerative Colitis Activity · Inflammatory Bowel Disease
- Truelove and Witts Severity Index for Ulcerative Colitis · Inflammatory Bowel Disease
- Ulcerative Colitis Endoscopic Index of Severity (UCEIS) · Inflammatory Bowel Disease
- Simplified Endoscopic Score for Crohn's Disease (SES-CD) · Inflammatory Bowel Disease
- Travis Criteria for Severe Ulcerative Colitis · Inflammatory Bowel Disease
- Pindolol · Non-selective β-blocker (with intrinsic sympathomimetic activity)
- Dapsone · Anti-inflammatory / Antimicrobial
- Methotrexate (Dermatology — Psoriasis) · Disease-Modifying Antirheumatic / Immunosuppressant
- Risankizumab · IL-23 Inhibitor — Psoriasis / Crohn's
- Colchicine · Anti-inflammatory — Neutrophilic Dermatoses / Vasculitis
- Acetazolamide (Ménière's Disease) · Carbonic Anhydrase Inhibitor (Diuretic)
Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.